Form 4: Annovis Bio Director Mark K. White Acquires Stock Options

Director Mark K. White acquired stock options in Annovis Bio, Inc. through transactions on November 17, 2023, November 27, 2023 and July 1, 2024.

Summary

• Mark K. White, a director of Annovis Bio, Inc., reported changes in beneficial ownership.
• On November 17, 2023, White acquired 26,200 stock options with an exercise price of $6.07, vesting immediately.
• On November 27, 2023, White acquired 2,146 stock options with an exercise price of $7.39, vesting immediately.
• On July 1, 2024, White acquired 20,000 stock options with an exercise price of $5.27, vesting quarterly.
• These options were granted in consideration for consulting services.
• The stock options are directly owned by White.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard stock option grants to a director, which is a common practice. The increase in shares issuable under the equity incentive plan is a slightly positive development.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
• The stock options granted for consulting services align the director's interests with the company's success.
• The approval of the amendment to the 2019 Equity Incentive Plan increases the number of shares issuable, providing more flexibility for future compensation and incentives.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of key personnel with shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grants as a way to incentivize the director to work towards increasing shareholder value.
• Employees may see the equity incentive plan as a positive sign, indicating potential for future compensation and incentives.

Key Dates